GlassScriptPhysician profile
Doreen Allison
NPI 1285642793
$4,730.40
in general payments reported to CMS, 2019-2025
20 companies · $98.44 in 2025
The $98.44 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $925 · 2022: $1,080 · 2023: $1,456 · 2024: $1,170 · 2025: $98.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.17 |
| Education | $150.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $974.40 | 2021-2024 | Caplyta |
| Abbvie INC. | $629.66 | 2021-2025 | |
| Lundbeck LLC | $610.97 | 2021-2025 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $532.83 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $459.06 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $336.17 | 2021-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $317.71 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $180.83 | 2021-2022 | |
| Axsome Therapeutics, INC. | $135.14 | 2022-2024 | Auvelity |
| Alkermes, INC. | $130.04 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Almatica Pharma LLC | $116.47 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $74.27 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $73.85 | 2022-2025 | Invega, Spravato |
| E.R. Squibb & Sons, L.L.C. | $44.78 | 2024 | Cobenfy |
| Indivior INC. | $31.03 | 2022-2023 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.71 | 2025 | Wegovy |
| Eisai INC. | $16.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.69 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $15.45 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doreen Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.